BOULDER, Colo., Aug. 19, 2016 /PRNewswire/ -- Array
BioPharma Inc. (NASDAQ: ARRY) today announced that results from a
Phase 2 study of ARRY-797 will be presented at the 2016 European
Society of Cardiology (ESC) Congress, which will be held
August 27 – 31, 2016 in Rome, Italy.
POSTER PRESENTATION
|
Title:
|
Phase 2 study of
A797, an oral, selective p38 mitogen-activated protein kinase
inhibitor, in patients with lamin A/C-related dilated
cardiomyopathy (Abstract #P4981)
|
|
Presenter:
|
Calum A. MacRae,
MD
|
|
Date:
|
Tuesday, August 30,
10:19 a.m. CEST
|
Updated and additional data will be provided at the
conference beyond what is included in the
abstract.
All abstracts can be accessed through the ESC website, or on
this web page:
http://spo.escardio.org/default.aspx?eevtid=1127.
The ARRY-797 abstract can be found by clicking this LINK.
About Array BioPharma
Array BioPharma Inc. is a
biopharmaceutical company focused on the discovery, development and
commercialization of targeted small molecule drugs to treat
patients afflicted with cancer. Five registration studies are
currently advancing related to three cancer drugs. These programs
include binimetinib (MEK162), encorafenib (LGX818) and selumetinib
(AstraZeneca). For more information on Array, please go to
www.arraybiopharma.com.
|
CONTACT:
|
Tricia
Haugeto
|
|
(303)
386-1193
|
|
thaugeto@arraybiopharma.com
|
Logo -
http://photos.prnewswire.com/prnh/20121029/LA02195LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/array-biopharma-announces-clinical-data-presentation-on-arry-797-at-the-2016-european-society-of-cardiology-congress-300316027.html
SOURCE Array BioPharma